Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. News
  7. Summary
    NANO   FR0011341205


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nanobiotix S.A. Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination

11/09/2021 | 04:15pm EST

Nanobiotix S.A. announced new preclinical immunotherapy data for novel, potentially solid tumor- and therapeutic combination-agnostic radioenhancer NBTXR3 that will be presented at the 2021 Annual Meeting of the Society for the mmunotherapy of Cancer (SITC). The Company believes that these data are consistent with recently presented clinical immunotherapy data and support advancement of development with anti-PD-1 and emerging immune checkpoint inhibitors. Preclinical data to be presented at the meeting by Nanobiotix (Abstract #740) show that radiotherapy-activated NBTXR3 increases CD8+ T cell infiltration and modulates the T cell receptor (?TCR?) repertoire, as well as marked modulation of immunopeptidome in treated tumor cells in a mouse model. Taken together, these variations could indicate that radiotherapy-activated NBTXR3 triggers more robust immune priming than radiotherapy alone and merits further evaluation of CD8+ response and abscopal effect. The Company?s perspective is that these data further support the mechanistic rationale of combining NBTXR3 with immune checkpoint inhibitors. The preclinical data follows preliminary clinical data presented earlier in the fourth quarter of 2021 from the phase I trial ("Study 1100") evaluating NBTXR3 in combination with the anti-PD-1 checkpoint inhibitors nivolumab (Opdivo?) or pembrolizumab (Keytruda?) in patients with locoregional recurrent ("LRR") or recurrent and metastatic ("R/M") head and neck squamous cell carcinoma ("HNSCC") or with lung or liver metastases from any primary cancer that is eligible for anti-PD-1 therapy. This preliminary data for Study 1100 showed an overall AE profile consistent with radiotherapy or anti-PD-1 monotherapies. A 56% target lesion objective response rate (80% in anti-PD-1 na?ve patients; 45% in prior non-responders) was observed in evaluable patients (n=16). A 50% overall objective response rate (% response in target and non-target lesions) was observed (80% in anti-PD-1 na?ve patients; 36% for prior non-responders) in evaluable patients. The potential immune priming effect of radiotherapy-activated NBTXR3 was observed in non-responders as well as anti-PD-1 na?ve patients, suggesting that NBTXR3 may reverse or circumvent resistance to prior anti-PD-1 treatment. Evaluation of novel combination approaches to immunotherapy continues to be a priority for Nanobiotix, as investigators seek to expand the impact of I/O agents for the 80-85% of patients that receive limited benefits, or no benefit at all, by improving response rates and overcoming resistance to anti-PD-1. TIGIT and LAG3, members of the same receptor class as CTLA-4 and PD-1, could be the next generation of immunotherapy targets and are being investigated alone and in combination with existing anti-PD-1 agents aiming to improve patient outcomes in clinical trials. The preclinical data to be presented at SITC by The University of Texas MD Anderson Cancer Center (Abstract #575) show that radiotherapy-activated NBTXR3 plus anti-PD-1, anti-TIGIT, and anti-LAG3 (?Combo therapy?) significantly promotes the proliferation activity of CD8+ T cells, improves local and distant tumor control, and increases survival rate in mice. Only the group of mice treated with the Combo therapy had survivors and those cured mice were immune to re-injection of tumor cells, maintained a significantly higher percentage of memory CD4+ and CD8+ memory T cells, and had stronger anti-tumor immune activities than the control, suggesting the induction of long-term anti-tumor memory by the Combo therapy.

© S&P Capital IQ 2021
All news about NANOBIOTIX
01/10NANOBIOTIX : Provides Corporate Update and Highlights Key 2022 Milestone Targets - Form 6-..
01/10NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
01/05Nanobiotix Enrolls First Patient In Late-Stage Trial For Head, Neck Cancer Treatment
01/05Nanobiotix Enrolls First Patient in Phase 3 Study of Head, Neck Cancer Treatment
01/05NANOBIOTIX : Announces First Patient Enrolled in NANORAY-312 Global Phase III Registration..
01/05NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registratio..
01/05Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Regist..
01/04Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 202..
2021NANOBIOTIX : Monthly statement on outstanding equity shares and voting rights
2021NANOBIOTIX : Monthly statement on outstanding equity shares and voting rights
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Sales 2021 2,30 M 2,61 M 2,61 M
Net income 2021 -68,1 M -77,2 M -77,2 M
Net cash 2021 74,1 M 84,1 M 84,1 M
P/E ratio 2021 -4,90x
Yield 2021 -
Capitalization 258 M 293 M 293 M
EV / Sales 2021 80,1x
EV / Sales 2022 103x
Nbr of Employees 98
Free-Float 94,5%
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | MarketScreener
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,42 €
Average target price 25,55 €
Spread / Average Target 244%
EPS Revisions
Managers and Directors
Laurent Lévy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323